The purpose of the study was to evaluate the effect of arsenic trioxide and cisplatin on Ehrlich ascites carcinoma (EAC) bearing mice. Fifty female Albino mice were separated into five groups. Group 1 considered the control. Groups 2 to 5 were injected 2.5 x 10⁶ EAC intraperitoneally (IP). Injected gp. 2 considered the positive control. Groups 3 and 4 received intraperitoneally injections of arsenic trioxide (ATO) (5 mg/kg) and cisplatin (CIP) (2 mg/kg)) daily for 14 days, while Group 5 received a combination of arsenic trioxide (ATO) (5 mg/kg) and cisplatin (CIP) (0.5 mg/kg)) daily for 14 days. After 14 days of treatment, blood samples were collected. Screening of the medications effects used for EAC treatment are carried out by mice body weights, body weight gain, and tumor growth inhibition by counting total, viable and non-viable tumor cells number for each group. Concurrently, liver functions (transaminases, total protein, and albumin) and kidney functions (urea and creatinine) were evaluated to reflect any clinical changes. The study shown that both ATO and CIP have synergetic properties against EAC.